DiaMedica Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

DiaMedica Therapeutics

06/05/2024 22:02

* DiaMedica Therapeutics Inc  DMAC.OQ   DMAC.O  is expected
to show no change in quarterly revenue when it reports 
results on May 8 for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for DiaMedica Therapeutics
Inc is
for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for DiaMedica
Therapeutics Inc is $7.00​, above​ its last closing price
of $3.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.14      -0.14     Met     0
 Sep. 30 2023  -0.14       -0.13      -0.12     Beat    5.3
 Jun. 30 2023  -0.19       -0.18      -0.16     Beat    9.4​
 Mar. 31 2023  -0.15       -0.16      -0.20     Missed  -25
 ​​Dec.                    -0.14      -0.14     Met     0
 31 2022                                                
 Sep. 30 2022  -0.13       -0.15      -0.12     Beat    18.6​
 Jun. 30 2022  -0.17       -0.18      -0.13     Beat    27.8
 Mar. 31 2022  -0.16       -0.21      -0.13     Beat    39.1
 This summary was machine generated May 6 at 21:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)